Formycon AG Adopts AI Tools for ~20% Efficiency Gain
Formycon AG is integrating AI-enabled eTMF and analytics into its biosimilar development process, with an internal assessment expecting approximately 20% efficiency improvements.
Formycon AG is integrating AI-enabled eTMF and analytics into its biosimilar development process, with an internal assessment expecting approximately 20% efficiency improvements.